Grantees Not In Danger Of Losing Cost-Free Biological Materials, But Can’t Have Chemicals
In Brief: NCI Scientists May Run For Congress; Upton Back Heroin For Terminal Cancer Patients
R. Lee Clark to Retire; Texas Starts Search for Successor
Drugs Available To Investigators Centers to Monitor Them Are Listed
FDA’s Young Still Not Satisfied With Distribution Plan
Tobacco Council Announces Awards
FDA Adopts Final Diagnostics X-Ray Rule Amendment
Trending Stories
- Franco Muggia, former head of CTEP and NYU cancer center, dies at 85
- Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group - House committee’s FY26 spending bill increases NCI funding by $48M, NIH by $99M
House joins Senate in rejecting Trump’s proposed 40% NIH cuts - Bhattacharya fields NCAB’s questions about funding, political involvement in grant review, DEI, animal testing
- Lowy: Forward-funding policy forced NCI to drastically reduce RPG awards funded for FY25, 10% of NCI staff has been lost
- Robert A. Winn on his new vision to train cancer center leaders: “I had a big bold idea and an ‘Aha!’ moment.”